Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
Gold Prices Hold Firm as Traders Watch U.S.-Iran Ceasefire and Trump-Xi Talks 
Oil Prices Rise as Dollar Gains Ahead of Key U.S. Inflation Data 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Indian Stock Market Drops as Iran Conflict Fuels Oil Price and Inflation Fears 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
ECB Signals Possible Interest Rate Move if Inflation Outlook Fails to Improve 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Moderna Inc. enters a historic $1 billion deal with China to research, develop, and produce exclusive mRNA medicines in the country. The agreement, announced amid growing Sino-American tensions, signifies Beijing's increasing openness to foreign pharmaceutical involvement.
The Cambridge, Massachusetts-based pharmaceutical and biotechnology company announced the new deal with Chinese officials on Wednesday, July 5. The agreement is for Moderna to research, develop and produce messenger RNA medicines in the country.
CNBC noted that an agreement was reached despite the growing tensions between China and the United States. Moderna and Beijing signed a memorandum of understanding (MOU) and land collaboration deal to develop drugs that will be made "exclusively for the Chinese people." This means the two sides agreed that the new drug would never be exported and remain in China.
A local media publication reported earlier this week that Moderna is set to invest about $1 billion in the project. It was added that Moderna's chief executive officer, Stephane Bancel, is set to visit Shanghai, possibly to talk more about the deal and for facility inspection.
"These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," the company's spokesman stated.
In a separate statement that was sent to Yahoo Finance, Moderna said, "We signed a memorandum of understanding and a related land collaboration agreement to work toward opportunities for Moderna to research, develop and manufacture mRNA medicines in China."
The deal shows that Moderna is trying to take advantage of the success of its COVID-19 vaccine that has been used on people worldwide. The vaccine used a platform called mRNA to push human cells to make an immune response against a virus. At any rate, the agreement was sealed on Wednesday, and this is Moderna's very first deal with the Chinese government.
Photo by: Ian Hutchinson/Unsplash
